Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a risk factor for mortality in patients with lung cancer. Nintedanib has been known to slow down the decline of lung function and reduce IPF exacerbation. We aimed to explore the feasibility of adding nintedanib to chemotherapy for non-small cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Makiguchi, Tomonori, Tanaka, Hisashi, Okudera, Koichi, Taima, Kageaki, Tasaka, Sadatomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183406/
https://www.ncbi.nlm.nih.gov/pubmed/37197621
http://dx.doi.org/10.21037/tlcr-22-699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183406/
https://www.ncbi.nlm.nih.gov/pubmed/37197621
http://dx.doi.org/10.21037/tlcr-22-699

Ejemplares similares